← Back to Clinical Trials
Recruiting NCT07400640

NCT07400640 Erector Spinae Plane Block Versus Transcutaneous Radiofrequency in Postherpetic Neuralgia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07400640
Status Recruiting
Phase
Sponsor Diskapi Teaching and Research Hospital
Condition Postherpetic Neuralgia
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2025-06-01
Primary Completion 2026-06-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL
Interventions
Erector Spinae Plane Block

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2025-06-01 with a primary completion date of 2026-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This observational study aims to compare the effectiveness of ultrasound-guided erector spinae plane (ESP) block and transcutaneous radiofrequency (RF) treatment in patients with postherpetic neuralgia. Pain intensity and neuropathic pain characteristics will be evaluated using the Visual Analog Scale (VAS) and the Self-Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) score.

Eligibility Criteria

Inclusion Criteria: Diagnosis of postherpetic neuralgia involving cervical, thoracic, or lumbar regions Age between 18 and 80 years Persistent pain despite conservative treatment Baseline VAS score \> 5 Exclusion Criteria: Ophthalmic or extremity postherpetic neuralgia Allergy to local anesthetics Pregnancy Coagulopathy or use of antiplatelet therapy Cognitive impairment preventing informed consent

Contact & Investigator

Central Contact

AYSE BETUL ACAR

✉ betulbozann@gmail.com

📞 +905326685180

Principal Investigator

AYSE BETUL ACAR

PRINCIPAL INVESTIGATOR

Diskapi TRH

Frequently Asked Questions

Who can join the NCT07400640 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Postherpetic Neuralgia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07400640 currently recruiting?

Yes, NCT07400640 is actively recruiting participants. Contact the research team at betulbozann@gmail.com for enrollment information.

Where is the NCT07400640 trial being conducted?

This trial is being conducted at Ankara, Turkey (Türkiye).

Who is sponsoring the NCT07400640 clinical trial?

NCT07400640 is sponsored by Diskapi Teaching and Research Hospital. The principal investigator is AYSE BETUL ACAR at Diskapi TRH. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology